certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | computed for the free peptide |
| Molecular weight | about 1419 Da | monoisotopic mass near 1418.7 |
| Amino acid count | 15 | single chain, no disulfide bonds |
| Solubility | freely soluble in water | also dissolves in saline and phosphate buffer |
| Common synonyms | pentadecapeptide BPC, BPC 157 | fragment notation varies by source |
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Therapeutic monoclonal antibodies (mAbs) are used for several diseases, including cancer and Rheumatoid arthritis. Consequently, the high immunogenicity limited efficacy and was associated with severe infusion reactions. Although the exact mechanism is unclear, it is suspected that the mAbs are inducing infusion reactions by eliciting antibody antigen interactions, such as increased formation of immunoglobulin E (IgE) antibodies, which may bind onto mast cells and subsequent degranulation, causing allergy-like symptoms as well as the release of additional cytokines. Several innovations in genetic engineering has resulted in the decrease in immunogenicity, (also known as deimmunization), of mAbs. Genetic engineering has led to the generation of humanized and chimeric antibodies, by exchanging the murine constant and complementary regions of the immunoglobulin chains with the human counterparts. Although this has reduced the sometimes extreme immunogenicity associated with murine mAbs, the anticipation that all fully human mAbs would have not possess unwanted immunogenic properties remains unfulfilled.
=== Recurring === Artemis Pebdani as Vice President Susan Ross Kate Burton as Sally Langston, former vice president George Newbern as Charlie Ricardo Chavira as Governor Francisco Vargas of Pennsylvania Mía Maestro as Elise Martin Gregg Henry as Hollis Doyle Norm Lewis as Senate Majority Leader Edison Davis Joelle Carter as Vanessa Moss Erica Shaffer as News Reporter Mackenzie Astin as Noah Baker John Prosky as Senator Gibson Rose Abdoo as Senator Linda Moskowitz Romy Rosemont as Patty Snell Paul Adelstein as Leo Bergen Brian Letscher as Tom Larsen Matthew Del Negro as Michael Ambruso Annabeth Gish as Lillian Forrester Danny Pino as Alejandro "Alex" Vargas
== Physiological relevance == Phosphatases act in opposition to kinases/phosphorylases, which add phosphate groups to proteins. The addition of a phosphate group may activate or de-activate an enzyme (e.g., kinase signalling pathways) or enable a protein-protein interaction to occur (e.g., SH2 domains ); therefore phosphatases are integral to many signal transduction pathways. Phosphate addition and removal do not necessarily correspond to enzyme activation or inhibition, and that several enzymes have separate phosphorylation sites for activating or inhibiting functional regulation. CDK, for example, can be either activated or deactivated depending on the specific amino acid residue being phosphorylated. Phosphates are important in signal transduction because they regulate the proteins to which they are attached. To reverse the regulatory effect, the phosphate is removed. This occurs on its own by hydrolysis, or is mediated by protein phosphatases. Protein phosphorylation plays a crucial role in biological functions and controls nearly every cellular process, including metabolism, gene transcription and translation, cell-cycle progression, cytoskeletal rearrangement, protein-protein interactions, protein stability, cell movement, and apoptosis. These processes depend on the highly regulated and opposing actions of PKs and PPs, through changes in the phosphorylation of key proteins. Histone phosphorylation, along with methylation, ubiquitination, sumoylation and acetylation, also regulates access to DNA through chromatin reorganisation.
===== Breast augmentation ===== The outcome of a breast augmentation with fat-graft injections depends upon proper patient selection, preparation, and correct technique for recipient site expansion, and the harvesting, refining, and injecting of the autologous breast filler fat. Technical success follows the adequate external vacuum expansion of the recipient-site tissues (matrix) before the injection of large-volume grafts (220–650 cc) of autologous fat to the breasts. After harvesting by liposuction, the breast-filler fat was obtained by low G-force syringe centrifugation of the harvested fat to separate it, by density, from the crystalloid component. The refined breast filler then was injected to the pre-expanded recipient site; post-procedure, the patient resumed continual vacuum expansion therapy upon the injected breast, until the next fat grafting session. The mean operating room (OR) time was 2-hours, and there occurred no incidences of infection, cysts, seroma, hematoma, or tissue necrosis. The breast-volume data reported in Breast Augmentation with Autologous Fat Grafting: A Clinical Radiological Study (2010) indicated a mean increase of 1.2 times the initial breast volume, at six months post-procedure. In a two-year period, 25 patients underwent breast augmentation by fat graft injection; at three weeks pre-procedure, before the fat grafting to the breast-tissue matrix (recipient site), the patients were photographed, and examined via intravenous contrast MRI or 3-D volumetric imaging, or both.
=== United Kingdom === In the United Kingdom, between 12,000 and 15,000 people are thought to have sickle cell disease with an estimated 250,000 carriers of the condition in England alone. As the number of carriers is only estimated, all newborn babies in the UK receive a routine blood test to screen for the condition. Due to many adults in high-risk groups not knowing if they are carriers, pregnant women and both partners in a couple are offered screening so they can get counselling if they have the sickle cell trait. In addition, blood donors from those in high-risk groups are also screened to confirm whether they are carriers and whether their blood filters properly. Donors who are found to be carriers are informed, and their blood, while often used for those of the same ethnic group, is not used for those with sickle cell disease who require a blood transfusion.
Sources: en.wikipedia.org
Schnitzer (1927), arts teacher and administrator Francis Steegmuller (1927), Flaubert scholar Gustave Von Groschwitz (1927), former director of the Carnegie Museum of Art Carl Benjamin Boyer (1928), historian of science and mathematics Leon Keyserling (1928), head of the Council of Economic Advisers under Harry S Truman Edgar Lorch (1928), mathematics department chairman at Columbia University Junius Bird (1930), archaeologist and former curator of South American Archaeology at the American Museum of Natural History Eli Ginzberg (1930), professor of economics at Columbia University Niels Henry Sonne (1930), rare book collector and head librarian at General Theological Seminary Maxwell Geismar (1931), literary critic, author, and professor at Sarah Lawrence College Francis Joseph Murray (1932), mathematician who developed the Von Neumann algebra with John von Neumann Walter H. Rubsamen (1933), professor of a musicology at the University of California, Los Angeles Joseph Leon Blau (1934), professor of religion at Columbia University M. A. Fitzsimons (1934), historian at the University of Notre Dame, editor of The Review of Politics Alan Gewirth (1934), philosopher, professor of philosophy at the University of Chicago, author of Reason and Morality Robert M.
Laboratory LOINC: It covers laboratory tests, microbiology tests (including antibiotic susceptibilities) Clinical LOINC: It covers a variety of non-lab concepts (ECG concepts, cardiac echo, obstetric ultrasound). Within clinical LOINC, there are also sup-parts for Clinical documents: concepts for various types of clinical reports (e.g., discharge summary, well-child visit note) Survey instruments: concepts for standardized surveys (e.g., Glasgow Coma Score, PHQ-9 depression scale)
=== Potency === By mass, salvinorin A "is the most potent naturally occurring hallucinogen." It is active at doses as low as 200 μg. Synthetic chemicals, such as LSD (active at 20–30 μg doses), can be more potent. Research has shown that salvinorin A is a potent and selective κ-opioid (kappa-opioid) receptor agonist. It has been reported that the effects of salvinorin A in mice are blocked by κ-opioid receptor antagonists. However, it is an even more potent D2 receptor partial agonist, and it is likely this action plays a significant role in its effects as well. Salvinorin A has no actions at the 5-HT2A serotonin receptor, the principal molecular target responsible for the actions of 'classic' hallucinogens, such as mescaline and LSD, nor is it known to have affinity for any other sites to date. In experiments, salvinorin A has shown little toxicity. Rodents chronically exposed to levels many times greater than those to which humans expose themselves show no signs of organ damage.
== Career == After earning his M.D., Sheiner did a three-year stint at Columbia Presbyterian Medical Center, first as an intern and then as a resident. He then served as a Research Associate at the National Institutes of Mental Health and the NIH Division of Computer Research and Technology. Sheiner completed his medical residency training at Stanford University in 1970. A two-year Clinical Pharmacology Fellowship at the University of California, San Francisco (UCSF) lead to a faculty position starting in 1972. He remained at UCSF for the remainder of his career, where hist last title was Professor of Laboratory Medicine, Medicine and Biopharmaceutical Sciences.
Due to the stabilization of 7s electronic orbitals and destabilization of 6d ones caused by relativistic effects, Cn2+ is likely to have a [Rn]5f146d87s2 electronic configuration, using the 6d orbitals before the 7s one, unlike its homologues. The fact that the 6d electrons participate more readily in chemical bonding means that once copernicium is ionized, it may behave more like a transition metal than its lighter homologues, especially in the possible +4 oxidation state. In aqueous solutions, copernicium may form the +2 and perhaps +4 oxidation states. The diatomic ion Hg2+2, featuring mercury in the +1 oxidation state, is well-known, but the Cn2+2 ion is predicted to be unstable or even non-existent. Copernicium(II) fluoride, CnF2, should be more unstable than the analogous mercury compound, mercury(II) fluoride (HgF2), and may even decompose spontaneously into its constituent elements. As the most electronegative reactive element, fluorine may be the only element able to oxidize copernicium even further to the +4 and even +6 oxidation states in CnF4 and CnF6; the latter may require matrix-isolation conditions to be detected, as in the disputed detection of HgF4. CnF4 should be more stable than CnF2. In polar solvents, copernicium is predicted to preferentially form the CnF−5 and CnF−3 anions rather than the analogous neutral fluorides (CnF4 and CnF2, respectively), although the analogous bromide or iodide ions may be more stable towards hydrolysis in aqueous solution. The anions CnCl2−4 and CnBr2−4 should also be able to exist in aqueous solution.
Sources: en.wikipedia.org
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.
In most jurisdictions it is not an approved medicine and is handled as a research material. Import and sale rules differ by country, and some regulators have placed it in categories that restrict human use. Status can change, so current local rules apply.
Rodent models dominate, particularly rats with induced gastric lesions, tendon injury, or vascular disruption. These designs allow controlled comparison but differ anatomically and metabolically from humans. Results from such models are commonly cited as preliminary.
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.